Pular para o conteúdo
Merck

O7125

L-Ornithine L-aspartate salt

≥98% (TLC)

Sinônimo(s):

(S)-2,5-Diaminopentanoic acid L-aspartate salt

Slide 1 of 3
Faça login para ver os preços organizacionais e de contrato.

Selecione um tamanho

Preço e disponibilidade não estão disponíveis no momento.

Sobre este item

Fórmula empírica (Notação de Hill):
C9H19N3O6
Número CAS:
3230-94-2
Peso molecular:
265.26
NACRES:
NA.26
PubChem Substance ID:
329818920
UNSPSC Code:
12352209
EC Number:
221-772-7
MDL number:
MFCD00058084

Documentos Principais

Visualizar Toda a Documentação

Pular para

Assistência Técnica
Precisa de ajuda? Nossa equipe de cientistas experientes está à sua disposição.
Estamos aqui para ajudar

Nome do produto

L-Ornithine L-aspartate salt, powder

InChI key

IXUZXIMQZIMPSQ-ZBRNBAAYSA-N

InChI

1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1

SMILES string

NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O

assay

≥98% (TLC)

form

powder

color

white to off-white

storage temp.

2-8°C

Quality Level

200

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Comparar Itens Semelhantes

Ver Comparação Total

Mostrar diferenças

1 of 4

Este Item
O2375O438675490
L-Ornithine L-aspartate salt powder

Sigma-Aldrich

O7125

L-Ornithine L-aspartate salt

L-Ornithine monohydrochloride ≥99%

Sigma-Aldrich

O2375

L-Ornithine monohydrochloride

L-Ornithine monohydrochloride BioXtra, ≥99%

Sigma-Aldrich

O4386

L-Ornithine monohydrochloride

DL-Ornithine monohydrochloride ≥99.0% (AT)

Sigma-Aldrich

75490

DL-Ornithine monohydrochloride

form

powder

form

powder

form

powder

form

powder

assay

≥98% (TLC)

assay

≥99%

assay

≥99%

assay

≥99.0% (AT)

storage temp.

2-8°C

storage temp.

-

storage temp.

-

storage temp.

-

color

white to off-white

color

white

color

white

color

-

Quality Level

200

Quality Level

200

Quality Level

200

Quality Level

100

Biochem/physiol Actions

L-Ornithine L-aspartate is a metabolite of arginine degradation by arginase. It has been shown to reduce blood ammonia concentrations by increasing ammoniadetoxification in the muscle and reducing the severity of hepatic encephalopathy in cirrhosis.

Other Notes

Product of arginine degradation by arginase

Classe de armazenamento

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
0000456907
0000456907
0000369173
0000369173
SLBW4848

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Imre Fehérvári et al.
Magyar sebeszet, 65(2), 58-62 (2012-04-20)
About 6500-7000 people/year die in Hungary due to liver cirrhosis which is often complicated with hepatic encephalopathy (HE). While conventional interpretation is that hepatic encephalopathy is a consequence of high blood ammonia level, recent data indicate that the degree of
Shahab Abid et al.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 21(11), 666-671 (2011-11-15)
To evaluate the efficacy of L-ornithine-L-aspartate (LOLA) as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy (HE). Randomized placebo controlled study. The Aga Khan University Hospital, Karachi in the year 2003-2004. Patients with HE were randomized to receive LOLA
José Luis Pérez Hernández et al.
Annals of hepatology, 10 Suppl 2, S66-S69 (2012-01-18)
Introduction. Hepatic encephalopathy (HE) refers to a complex neuropsychiatric syndrome that is progressive but potentially reversible and may have a significant impact on quality of life, as it is characterized by alterations in cognitive function, behavior and personality as well
Marsha Y Morgan et al.
Metabolic brain disease, 22(3-4), 389-405 (2007-09-12)
Current recommendations for the treatment of hepatic encephalopathy are based, to a large extent, on open or uncontrolled trials, undertaken in very small numbers of patients. In consequence, there is ongoing discussion as to whether the classical approach to the
Takeyori Saheki et al.
Scientific reports, 9(1), 4179-4179 (2019-03-14)
Previous studies using citrin/mitochondrial glycerol-3-phosphate (G3P) dehydrogenase (mGPD) double-knockout mice have demonstrated that increased dietary protein reduces the extent of carbohydrate-induced hyperammonemia observed in these mice. This study aimed to further elucidate the mechanisms of this effect. Specific amino acids
Exibir todos os documentos relacionados

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica